Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 13.07 -0.24 (-1.8%) Market Cap: 1.12 Bil Enterprise Value: 710.08 Mil PE Ratio: 0 PB Ratio: 3.04 GF Score: 32/100

Syndax Pharmaceuticals Inc at UBS Global Healthcare Conference Transcript

May 21, 2019 / 02:30PM GMT
Release Date Price: $7.32 (+2.38%)
Unidentified Analyst

Thank you for coming to the 2019 UBS Global Healthcare Conference. My name is [Hanna], and I'll be your host for this session. Our next speaker is Briggs Morrison, CEO, of Syndax Pharmaceuticals. There will be a breakout session in Uris downstairs and the conference staff will point you to the correct direction. Thank you.

Briggs W. Morrison
Syndax Pharmaceuticals, Inc. - CEO & Director

Thanks very much, Hanna. I'm Briggs Morrison, the CEO of Syndax. Our vision as a company is to realize a future, in which patients with cancer live longer and better than ever before. And we think we have the molecules to be able to do that. We think we have an incredible team of employees that can do that, and we've been very fortunate to have a great group of investors who have supported our vision. And I'll bring you up to date today on where we are in our progress along this journey.

The forward-looking statements disclosure. So here's our pipeline as of today. I'll spend most of my time talking about the entinostat-exemestane program that's in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot